Topic Listing for Enzo Biochem

Accrued Liabilities Other Current Accumulated Other Comprehensive Income Loss
Acquisition Acquisitions
Adequacy Insurance Purchase Cover Potential Business Risk Adverse Perception Increased Regulatory Scrutiny Gene Medicine Genetic
Advertising Also Listen Over Internet
Amendments Amendments Articles Incorporation Bylaws Change
Annual Cash Bonus Annual Meeting
Annual Meeting Shareholders Held 2008 Annual Meeting Shareholders Held 2009
Anti Fraud Abuse Laws Apply Biomedical Research Products Clinical Diagnostics Market
Apply Biomedical Research Technology Clinical Diagnostics Market Apply Innovative Technology Infectious Immune Mediated Disease Markets
Art Art Other Information
Assay Designs Inc Assignment Policies
Audit Committee Audit Committee Report
Audit Fees Audit-related Fees
Background Base Salary
Basis Presentation Because Competitive Pressures Complexity Expense Billing Process Clinical
Because Not Intend Pay Cash Dividends Common Stock Beneficial Ownership Reporting Compliance
Benefits Other Compensation Biographical Information Regarding Directors Executive Officers
Biographical Information Regarding Directors Executive Officers Key Employees Biomol International
Board Access Independent Advisors Board Committee Charters
Board Committees Board Directors
Board Directors Stockholders Enzo Biochem Inc Board Nomination Policies Procedure
Business Combinations Cash Equivalents
Cell Signaling Pathway Certain Relationships Related Transactions
Certificate Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Certification Pursuant 302 Sarbanes-oxley Act 2002
Certification Pursuant Title Usc 1350 Adopted 906 Sarbanes-oxley Certifications
Changes Internal Control Over Financial Reporting Class Term Expire 2009
Class Term Expire 2010 Class Term Expire 2011
Class Term Expire 2012 Clinical Diagnostics
Clinical Laboratory Business Subject Extensive Government Regulation Loss Clinical Laboratory Regulations
Clinical Laboratory Services Code Ethics
Collection Death Proceeds Commitments
Common Stock Offerings Communications Board Directors
Compare 5-year Cumulative Total Return Among Enzo Biochem Compared 2005
Compared 2006 Consolidated Results Compared 2007
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Directors Compensation Discussion Analysis
Competition Completion Acquisition Disposition Assets
Compliance Hipaa Security Regulations Privacy Increase Costs Compliance Medicare Administrative Policies Including Those Pertaining Certain
Components Executive Compensation Program Comprehensive Income Loss
Comprehensive Loss Concentration Credit Risk
Conduct Conference Call 2009 830 Edt Accessed Dialing Conference Call
Conference Call Conducted Enzo Biochem Inc Management Take Confidentiality Health Information
Consolidated Results Contact
Contingences Contingencies
Contracts Checks Drafts Bank Accounts Etc Contractual Adjustment
Contractual Obligations Controls Procedures
Core Technologies Corporate Code Ethics
Corporate Governance Corporate Governance Guidelines
Corporate Governance Policies Practices Current Report Pursuant Securities Exchange Act 1934
Departure Directors Certain Officers Election Appointment Compensatory Depend Distributors Contract Manufacturers Suppliers Materials Impair Ability
Difficult Party Acquire Inhibit Stockholders Realizing Premium Stock Direct Communications
Director Compensation Table Director Independence
Director Nominations Directors Continuing Office
Directors Executive Officers Key Employees Distribution Arrangements
Effect New Accounting Pronouncements Employee Benefit Plan
Employees Employment Agreements
Entry Material Definitive Agreement Enzo
Enzo Biochem Enzo Biochem Announces Record 2009 Revenues Revenue Life
Enzo Biochem Inc Enzo Biochem Inc Announces Departure Secretary Treasurer
Enzo Biochem Inc Except Per Share Data Selected Enzo Biochem Reports Record Revenue
Enzo Biochem Reports Record Revenues Significantly Improved Operating Enzo Biochem Reports Sharply Improved Results Record Revenues
Enzo Biochem Reports Six-month Results ----- Three- Revenues Enzo Clinical Labs
Enzo Life Sciences Enzo Therapeutics
Enzo Website Estimates
Evaluation Disclosure Controls Procedures Executive Other Committees
Executive Sessions Non-management Directors Exhibits
Expand Collaborations Major Life Sciences Companies Expand Marketing Distribution Infrastructure
Expand Protect Intellectual Property Estate Experienced Significant Losses Last Such Continue Value Investment
Explanatory External Research Collaborations
Face Intense Competition Cause Decrease Prices Products Services Fail Attract Retain Key Personnel Including Senior Management
Fair Value Measurement Fair Value Measurements
Family Relationships Fda Regulation Laboratory-developed Tests Analyte Specific Reagents Genetic
Financial Statements Exhibits Foreign Currency Exchange Rate Fluctuations Adversely Affect Business
Foreign Currency Exchange Rate Risk Foreign Currency Translation
Forum Non Conveniens Forward Looking Cautionary Statements
Forward-looking Statements Full Results
Future Success Depend Part Ability Enhance Existing Products Gene Analysis Technology
Gene Regulation General
Goodwill Goodwill Indefinite-lived Intangibles
Goodwill Intangible Assets Grants Equity Awards 2008
Guarantees Future Performance Involve Number Risks Uncertainties Materially Hazardous Materials Business Claims Relating Improper Handling Storage
Hepatitis Virus Hbv Householding Annual Meeting Materials
Human Immunodeficiency Virus Hiv-1 Ignatures
Immune Regulation Immunoassay Development
Impairment Long-lived Assets Inability Carry Out Certain Marketing Sales Plans Make
Income Taxes Incur Impairment Charges Goodwill Other Intangible Assets Indefinite
Indemnification Index
Information Systems Insurance Indemnification Directors Officers
Insurance Purchase Cover Potential Business Risk Inadequate Intangible Assets
Intellectual Property Interest Rate Risk
Internal Research Programs Inventories
Inventory Ist Consolidated Financial Statements Statement Schedule
Lead Independent Director Charter Leases
Leverage Marketing Distribution Infrastructure Leading Life Sciences Companies License Fees Multiple Element Arrangements
Licensing Supply Agreement Liquidity Capital Resources
Managements Annual Report Internal Control Over Financial Reporting Manufacturing Research Facilities
Marketable Securities Maximize Resources Collaborating Others Research Commercialization Activities
Medical Regulated Waste Meeting Shareholders
Meetings Board Directors Committees Net Income Loss Per Share
Net Loss Income Per Share Net Loss Per Share
New York Nomination Procedure
Nominations Board Directors Non-alcoholic Steatohepatitis Nash
Notes Notice Annual Meeting Shareholders Held 2008
Notice Hereby Given Nucleic Acid Analysis Format
Nucleic Acid Chemistry Objectives Philosophy Executive Compensation Program
Occupational Safety Office
Officers Operating Results
Operating Results Vary Period Operating Segments
Options Exercised Stock Vested Osteoporosis Certain Bone Disorders
Osteoporosis Certain Bone Disorders Diabetes Other Compensation 2007
Other Compensation 2008 2007 Other Events
Other Fees Other Regulation
Overview Ownership Policies
Part 8211 Other Information Part Other Information
Payment Payments Due Period
Performance Graph Potential Payments Termination Change Control
Principles Consolidation Product Revenues
Products Services Property Plant Equipment
Proposal Approval Independent Registered Public Accounting Firm Proposal Election Director
Protecting Proprietary Rights Difficult Costly Fail Adequately Protect Proxy Solicited Behalf Board Directors
Ptions Exercised Stock Vested Quality Assurance
Quantitative Qualitative Disclosures Market Risk Recent Accounting Pronouncements
Recent Developments Recent Events
Reclassifications Regulation Diagnostics
Regulation Disclosure Regulation Pharmaceutical Products
Regulations Requiring Standard Transactions Healthcare Services Issued Health Reimbursement Premiums Advanced
Release Collateral Assignment Replay Conference Call Accessed Dialing 1-800-642-1687 Prompted Pin
Report Independent Registered Public Accounting Firm Requirements
Research Development Research Products
Restricted Stock Awards Results Operations 2007 Compared 2006
Results Operations 2008 Compared 2007 Results Operations Financial Condition
Revenues Clinical Laboratory Services Risks Relating Clinical Labs Services Segment
Royalties Royalty Licensing Income
Royalty Other Income Rule 14a-101
Safe Harbor Statement Sales Marketing
Sarbanes-oxley Act 2002 Sciences Gross Profit Rises
Scientific Depth Seal
Securities Authorized Issuance Equity Compensation Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Registered Pursuant Act
See Segment Analysis
Segment Reporting Segment Results
Severance Change-of-control Benefits Share-based Compensation
Shareholder Proposals Director Nominations Presented Next Annual Meeting Shares Etc
Shipping Handling Costs Short Term Investments
Short-term Investments Signal Delivery
Signatures Small Molecule Development
Stock Dividends Stock Option Plans
Stock Price Been Volatile Result Substantial Losses Investors Strategy
Subject Economic Political Other Risks Associated Significant International Subsequent Event
Summary Significant Accounting Policies Supplemental Disclosure Statement Cash Flows
Table Contents Tax Accounting Considerations
Tax Fees Tem Controls Procedures
Tem Managements Discussion Analysis Financial Condition Results Operations Tem Quantitative Qualitative Disclosures Market Risk
Termination Split Dollar Agreement Termination Split Dollar Life Insurance Agreements
Therapeutic Development Programs Therapeutic Technology Platforms
Therapeutics Tools Biomedical Pharmaceutical Research
Treasury Stock Unable Identify Acquire Integrate Acquisition Targets
Unable Obtain Maintain Regulatory Approvals Products Reduce Revenue United States Securities Exchange Washington 20549 Form 10-k
Unregistered Sales Equity Securities Voting Securities
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki